Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 770

1.

Glycation of the Major Milk Allergen β-Lactoglobulin Changes its Allergenicity by Alterations in Cellular Uptake and Degradation.

Perusko M, van Roest M, Stanic-Vucinic D, Simons PJ, Pieters R, Velickovic TC, Smit JJ.

Mol Nutr Food Res. 2018 Jul 13:e1800341. doi: 10.1002/mnfr.201800341. [Epub ahead of print]

PMID:
30004175
2.

Global methylation in relation to methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.

Oosterom N, Griffioen PH, den Hoed MAH, Pieters R, de Jonge R, Tissing WJE, van den Heuvel-Eibrink MM, Heil SG.

PLoS One. 2018 Jul 9;13(7):e0199574. doi: 10.1371/journal.pone.0199574. eCollection 2018.

3.

A decrease in vitamin D levels is associated with methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.

Oosterom N, Dirks NF, Heil SG, de Jonge R, Tissing WJE, Pieters R, van den Heuvel-Eibrink MM, Heijboer AC, Pluijm SMF.

Support Care Cancer. 2018 Jun 19. doi: 10.1007/s00520-018-4312-0. [Epub ahead of print]

PMID:
29922939
4.

Representing the Process of Inflammation as Key Events in Adverse Outcome Pathways.

Villeneuve DL, Landesmann B, Allavena P, Ashley N, Bal-Price A, Corsini E, Halappanavar S, Hussell T, Laskin D, Lawrence T, Nikolic-Paterson D, Pallardy M, Paini A, Pieters R, Roth R, Tschudi-Monnet F.

Toxicol Sci. 2018 Jun 1;163(2):346-352. doi: 10.1093/toxsci/kfy047.

PMID:
29850905
5.

Anti-leukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4+ infant ALL.

Bardini M, Trentin L, Rizzo F, Vieri M, Savino AM, Garrido Castro P, Fazio G, Van Roon EHJ, Kerstjens M, Smithers NN, Prinjha RK, Te Kronnie G, Basso G, Stam RW, Pieters R, Biondi A, Cazzaniga G.

Mol Cancer Ther. 2018 May 10. pii: molcanther.1123.2017. doi: 10.1158/1535-7163.MCT-17-1123. [Epub ahead of print]

PMID:
29748211
6.

Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group.

van der Sluis IM, de Groot-Kruseman H, Te Loo M, Tissing WJE, van den Bos C, Kaspers GJL, Bierings M, Kollen WJW, König T, Pichlmeier U, Kühnel HJ, Pieters R.

Pediatr Blood Cancer. 2018 Aug;65(8):e27083. doi: 10.1002/pbc.27083. Epub 2018 May 4.

PMID:
29727043
7.

Probing the Inhibitor versus Chaperone Properties of sp²-Iminosugars towards Human β-Glucocerebrosidase: A Picomolar Chaperone for Gaucher Disease.

Mena-Barragán T, García-Moreno MI, Sevšek A, Okazaki T, Nanba E, Higaki K, Martin NI, Pieters RJ, Fernández JMG, Mellet CO.

Molecules. 2018 Apr 17;23(4). pii: E927. doi: 10.3390/molecules23040927.

8.

Demystifying O-GlcNAcylation: hints from peptide substrates.

Shi J, Ruijtenbeek R, Pieters RJ.

Glycobiology. 2018 Mar 22. doi: 10.1093/glycob/cwy031. [Epub ahead of print]

PMID:
29635275
9.

Type 2 diabetes-related proteins derived from an in vitro model of inflamed fat tissue.

Ten Klooster JP, Sotiriou A, Boeren S, Vaessen S, Vervoort J, Pieters R.

Arch Biochem Biophys. 2018 Apr 15;644:81-92. doi: 10.1016/j.abb.2018.03.003. Epub 2018 Mar 8.

PMID:
29526533
10.

Three-dimensional analysis of the fast-start escape response of the least killifish, Heterandria formosa.

Fleuren M, van Leeuwen JL, Quicazan-Rubio EM, Pieters RPM, Pollux BJA, Voesenek CJ.

J Exp Biol. 2018 Apr 6;221(Pt 7). pii: jeb168609. doi: 10.1242/jeb.168609.

PMID:
29487155
11.

Thiodigalactoside-Bovine Serum Albumin Conjugates as High-Potency Inhibitors of Galectin-3: An Outstanding Example of Multivalent Presentation of Small Molecule Inhibitors.

Zhang H, Laaf D, Elling L, Pieters RJ.

Bioconjug Chem. 2018 Apr 18;29(4):1266-1275. doi: 10.1021/acs.bioconjchem.8b00047. Epub 2018 Mar 7.

12.

Fish consumption from urban impoundments: What are the health risks associated with DDTs and other organochlorine pesticides in fish to township residents of a major inland city.

Pheiffer W, Wolmarans NJ, Gerber R, Yohannes YB, Ikenaka Y, Ishizuka M, Smit NJ, Wepener V, Pieters R.

Sci Total Environ. 2018 Jul 1;628-629:517-527. doi: 10.1016/j.scitotenv.2018.02.075. Epub 2018 Feb 13.

PMID:
29453181
13.

The Role of Excipients in the Stability of Triamcinolone Acetonide in Ointments.

van Heugten AJP, de Vries WS, Markesteijn MMA, Pieters RJ, Vromans H.

AAPS PharmSciTech. 2018 Apr;19(3):1448-1453. doi: 10.1208/s12249-018-0957-8. Epub 2018 Feb 15.

PMID:
29450828
14.

Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo.

Kerstjens M, Pinhancos SS, Castro PG, Schneider P, Wander P, Pieters R, Stam RW.

Haematologica. 2018 Apr;103(4):e147-e150. doi: 10.3324/haematol.2017.174060. Epub 2018 Feb 1. No abstract available.

15.

Topically used corticosteroids: What is the big picture of drug product degradation?

van Heugten AJP, de Boer W, de Vries WS, Pieters RJ, Vromans H.

Eur J Pharm Sci. 2018 May 30;117:1-7. doi: 10.1016/j.ejps.2018.02.001. Epub 2018 Feb 3.

PMID:
29407556
16.

Polycyclic aromatic hydrocarbons (PAHs) in sediments from a typical urban impacted river: application of a comprehensive risk assessment.

Pheiffer W, Quinn LP, Bouwman H, Smit NJ, Pieters R.

Ecotoxicology. 2018 Apr;27(3):336-351. doi: 10.1007/s10646-018-1898-4. Epub 2018 Feb 5.

PMID:
29404865
17.

Tissue influx of neutrophils and monocytes is delayed during development of trovafloxacin-induced tumor necrosis factor-dependent liver injury in mice.

Giustarini G, Kruijssen L, van Roest M, Bleumink R, Weaver RJ, Bol-Schoenmakers M, Smit J, Pieters R.

J Appl Toxicol. 2018 May;38(5):753-765. doi: 10.1002/jat.3585. Epub 2018 Jan 26.

PMID:
29377180
18.

High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia.

Steeghs EMP, Bakker M, Hoogkamer AQ, Boer JM, Hartman QJ, Stalpers F, Escherich G, de Haas V, de Groot-Kruseman HA, Pieters R, den Boer ML.

Sci Rep. 2018 Jan 12;8(1):693. doi: 10.1038/s41598-017-17704-4.

19.

Health-related fitness in very long-term survivors of childhood cancer: A cross-sectional study.

Hartman A, Pluijm SMF, Wijnen M, Neggers SJCMM, Clemens E, Pieters R, van den Heuvel-Eibrink MM.

Pediatr Blood Cancer. 2018 Apr;65(4). doi: 10.1002/pbc.26907. Epub 2017 Dec 22.

PMID:
29271565
20.

"In vitro" studies on galectin-3 in human natural killer cells.

Brittoli A, Fallarini S, Zhang H, Pieters RJ, Lombardi G.

Immunol Lett. 2018 Feb;194:4-12. doi: 10.1016/j.imlet.2017.12.004. Epub 2017 Dec 14.

PMID:
29248489
21.

A systematic review of exercise and psychosocial rehabilitation interventions to improve health-related outcomes in patients with bladder cancer undergoing radical cystectomy.

Rammant E, Decaestecker K, Bultijnck R, Sundahl N, Ost P, Pauwels NS, Deforche B, Pieters R, Fonteyne V.

Clin Rehabil. 2018 May;32(5):594-606. doi: 10.1177/0269215517746472. Epub 2017 Dec 12.

PMID:
29231044
22.

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.

Driessen EMC, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, Vora A, Hovi L, Escherich G, Li CK, Mann G, Leblanc T, Locatelli F, Biondi A, Rubnitz J, Schrappe M, Silverman L, Stary J, Suppiah R, Szczepanski T, Valsecchi M, Pieters R.

Leukemia. 2017 Dec;31(12):2854. doi: 10.1038/leu.2017.279.

PMID:
29210366
23.

A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.

Sutton R, Venn NC, Law T, Boer JM, Trahair TN, Ng A, Den Boer ML, Dissanayake A, Giles JE, Dalzell P, Mayoh C, Barbaric D, Revesz T, Alvaro F, Pieters R, Haber M, Norris MD, Schrappe M, Dalla Pozza L, Marshall GM.

Br J Haematol. 2018 Feb;180(4):550-562. doi: 10.1111/bjh.15056. Epub 2017 Nov 30.

PMID:
29194562
24.

High PDGFRA expression does not serve as an effective therapeutic target in ERG-deleted B-cell precursor acute lymphoblastic leukemia.

Jerchel IS, Chatzivasileiou D, Hoogkamer AQ, Boer JM, Beverloo HB, Pieters R, den Boer ML.

Haematologica. 2018 Feb;103(2):e73-e77. doi: 10.3324/haematol.2017.171702. Epub 2017 Nov 23. No abstract available.

25.

JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia.

Steeghs EMP, Jerchel IS, de Goffau-Nobel W, Hoogkamer AQ, Boer JM, Boeree A, van de Ven C, Koudijs MJ, Besselink NJM, de Groot-Kruseman HA, Zwaan CM, Horstmann MA, Pieters R, den Boer ML.

Oncotarget. 2017 Sep 16;8(52):89923-89938. doi: 10.18632/oncotarget.21027. eCollection 2017 Oct 27.

26.

Site of childhood cancer care in the Netherlands.

Reedijk AMJ, van der Heiden-van der Loo M, Visser O, Karim-Kos HE, Lieverst JA, de Ridder-Sluiter JG, Coebergh JWW, Kremer LC, Pieters R.

Eur J Cancer. 2017 Dec;87:38-46. doi: 10.1016/j.ejca.2017.09.030. Epub 2017 Nov 3.

PMID:
29107860
27.

Rationally Designed Chemically Modified Glycodendrimer Inhibits Streptococcus suis Adhesin SadP at Picomolar Concentrations.

Haataja S, Verma P, Fu O, Papageorgiou AC, Pöysti S, Pieters RJ, Nilsson UJ, Finne J.

Chemistry. 2018 Feb 6;24(8):1905-1912. doi: 10.1002/chem.201704493. Epub 2018 Jan 5.

PMID:
29094420
28.

TCF21 hypermethylation regulates renal tumor cell clonogenic proliferation and migration.

Gooskens SL, Klasson TD, Gremmels H, Logister I, Pieters R, Perlman EJ, Giles RH, van den Heuvel-Eibrink MM.

Mol Oncol. 2018 Feb;12(2):166-179. doi: 10.1002/1878-0261.12149. Epub 2017 Dec 14.

29.

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.

Cazzaniga G, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen HO, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari GM, Bleckmann K, Pieters R, van der Velden V, Stary J, Zuna J, Escherich G, Stadt UZ, Aricò M, Conter V, Schrappe M, Valsecchi MG, Biondi A.

Haematologica. 2018 Jan;103(1):107-115. doi: 10.3324/haematol.2017.176917. Epub 2017 Oct 27.

30.

Improved Efficacy of Oral Immunotherapy Using Non-Digestible Oligosaccharides in a Murine Cow's Milk Allergy Model: A Potential Role for Foxp3+ Regulatory T Cells.

Vonk MM, Diks MAP, Wagenaar L, Smit JJ, Pieters RHH, Garssen J, van Esch BCAM, Knippels LMJ.

Front Immunol. 2017 Sep 29;8:1230. doi: 10.3389/fimmu.2017.01230. eCollection 2017.

31.

The efficacy of oral and subcutaneous antigen-specific immunotherapy in murine cow's milk- and peanut allergy models.

Vonk MM, Wagenaar L, Pieters RHH, Knippels LMJ, Willemsen LEM, Smit JJ, van Esch BCAM, Garssen J.

Clin Transl Allergy. 2017 Sep 29;7:35. doi: 10.1186/s13601-017-0170-y. eCollection 2017.

32.

RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.

Jerchel IS, Hoogkamer AQ, Ariës IM, Steeghs EMP, Boer JM, Besselink NJM, Boeree A, van de Ven C, de Groot-Kruseman HA, de Haas V, Horstmann MA, Escherich G, Zwaan CM, Cuppen E, Koudijs MJ, Pieters R, den Boer ML.

Leukemia. 2018 Apr;32(4):931-940. doi: 10.1038/leu.2017.303. Epub 2017 Oct 3.

33.

Clean Intermittent Self-Catheterization as a Treatment Modality for Urinary Retention: Perceptions of Urologists.

Weynants L, Hervé F, Decalf V, Kumps C, Pieters R, Troyer B, Everaert K.

Int Neurourol J. 2017 Sep;21(3):189-196. doi: 10.5213/inj.1734824.412. Epub 2017 Sep 12.

34.

Affinity capillary electrophoresis for the assessment of binding affinity of carbohydrate-based cholera toxin inhibitors.

Aizpurua-Olaizola O, Sastre Torano J, Pukin A, Fu O, Boons GJ, de Jong GJ, Pieters RJ.

Electrophoresis. 2018 Jan;39(2):344-347. doi: 10.1002/elps.201700207. Epub 2017 Oct 4.

PMID:
28905402
35.

MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML.

Larmonie NSD, Arentsen-Peters TCJM, Obulkasim A, Valerio D, Sonneveld E, Danen-van Oorschot AA, de Haas V, Reinhardt D, Zimmermann M, Trka J, Baruchel A, Pieters R, van den Heuvel-Eibrink MM, Zwaan CM, Fornerod M.

Oncogene. 2018 Jan 4;37(1):107-115. doi: 10.1038/onc.2017.293. Epub 2017 Sep 11.

PMID:
28892045
36.

The role of constitutive activation of FMS-related tyrosine kinase-3 and NRas/KRas mutational status in infants with KMT2A-rearranged acute lymphoblastic leukemia.

Fedders H, Alsadeq A, Schmäh J, Vogiatzi F, Zimmermann M, Möricke A, Lenk L, Stadt UZ, Horstmann MA, Pieters R, Schrappe M, Stanulla M, Cario G, Schewe DM.

Haematologica. 2017 Nov;102(11):e438-e442. doi: 10.3324/haematol.2017.169870. Epub 2017 Aug 24. No abstract available.

37.

A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.

Kloos RQH, Uyl-de Groot CA, van Litsenburg RRL, Kaspers GJL, Pieters R, van der Sluis IM.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26651. Epub 2017 Aug 2.

PMID:
28766887
38.

The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.

Garrido Castro P, van Roon EHJ, Pinhanços SS, Trentin L, Schneider P, Kerstjens M, Te Kronnie G, Heidenreich O, Pieters R, Stam RW.

Leukemia. 2018 Feb;32(2):323-331. doi: 10.1038/leu.2017.216. Epub 2017 Jul 10.

PMID:
28690313
39.

Indole-3-carbinol, a plant nutrient and AhR-Ligand precursor, supports oral tolerance against OVA and improves peanut allergy symptoms in mice.

Hammerschmidt-Kamper C, Biljes D, Merches K, Steiner I, Daldrup T, Bol-Schoenmakers M, Pieters RHH, Esser C.

PLoS One. 2017 Jun 30;12(6):e0180321. doi: 10.1371/journal.pone.0180321. eCollection 2017.

40.

The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia.

Gutierrez-Camino A, Oosterom N, den Hoed MAH, Lopez-Lopez E, Martin-Guerrero I, Pluijm SMF, Pieters R, de Jonge R, Tissing WJE, Heil SG, García-Orad A, van den Heuvel-Eibrink MM.

Pharmacogenet Genomics. 2017 Aug;27(8):303-306. doi: 10.1097/FPC.0000000000000291.

PMID:
28628559
41.

Acute lymphoblastic leukemia cells create a leukemic niche without affecting the CXCR4/CXCL12 axis.

de Rooij B, Polak R, van den Berk LCJ, Stalpers F, Pieters R, den Boer ML.

Haematologica. 2017 Oct;102(10):e389-e393. doi: 10.3324/haematol.2016.159517. Epub 2017 Jun 15. No abstract available.

42.

Eating behavior during dexamethasone treatment in children with acute lymphoblastic leukemia.

Warris LT, van den Akker ELT, Bierings MB, van den Bos C, Aarsen FK, Zwaan MC, Tissing WJE, Veening MA, Pieters R, van den Heuvel-Eibrink MM.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26679. Epub 2017 Jun 9.

PMID:
28598548
43.

Application of Caenorhabditis elegans (nematode) and Danio rerio embryo (zebrafish) as model systems to screen for developmental and reproductive toxicity of Piperazine compounds.

Racz PI, Wildwater M, Rooseboom M, Kerkhof E, Pieters R, Yebra-Pimentel ES, Dirks RP, Spaink HP, Smulders C, Whale GF.

Toxicol In Vitro. 2017 Oct;44:11-16. doi: 10.1016/j.tiv.2017.06.002. Epub 2017 Jun 26.

PMID:
28595837
44.

Rehabilitation interventions to improve patient-reported outcomes and physical fitness in survivors of muscle invasive bladder cancer: a systematic review protocol.

Rammant E, Bultijnck R, Sundahl N, Ost P, Pauwels NS, Deforche B, Pieters R, Decaestecker K, Fonteyne V.

BMJ Open. 2017 Jun 6;7(5):e016054. doi: 10.1136/bmjopen-2017-016054. Review.

45.

Peptide microarray analysis of the cross-talk between O-GlcNAcylation and tyrosine phosphorylation.

Shi J, Tomašič T, Sharif S, Brouwer AJ, Anderluh M, Ruijtenbeek R, Pieters RJ.

FEBS Lett. 2017 Jul;591(13):1872-1883. doi: 10.1002/1873-3468.12708. Epub 2017 Jun 27.

46.

Measuring O-GlcNAc cleavage by OGA and cell lysates on a peptide microarray.

Sharif S, Shi J, Bourakba M, Ruijtenbeek R, Pieters RJ.

Anal Biochem. 2017 Sep 1;532:12-18. doi: 10.1016/j.ab.2017.05.027. Epub 2017 May 29.

47.

Application of the adverse outcome pathway (AOP) concept to structure the available in vivo and in vitro mechanistic data for allergic sensitization to food proteins.

van Bilsen JHM, Sienkiewicz-Szłapka E, Lozano-Ojalvo D, Willemsen LEM, Antunes CM, Molina E, Smit JJ, Wróblewska B, Wichers HJ, Knol EF, Ladics GS, Pieters RHH, Denery-Papini S, Vissers YM, Bavaro SL, Larré C, Verhoeckx KCM, Roggen EL.

Clin Transl Allergy. 2017 May 12;7:13. doi: 10.1186/s13601-017-0152-0. eCollection 2017. Review.

48.

TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.

Klaassen ILM, Lauw MN, van de Wetering MD, Biemond BJ, Middeldorp S, Abbink FCH, Bierings M, Te Loo DMMW, Pieters R, van der Sluis IM, Tissing WJE, Michel Zwaan C, Heleen van Ommen C.

BMC Pediatr. 2017 May 10;17(1):122. doi: 10.1186/s12887-017-0877-x.

49.

Tunneling nanotubes facilitate autophagosome transfer in the leukemic niche.

de Rooij B, Polak R, Stalpers F, Pieters R, den Boer ML.

Leukemia. 2017 Jul;31(7):1651-1654. doi: 10.1038/leu.2017.117. Epub 2017 Apr 12. No abstract available.

50.

Classification of pediatric acute myeloid leukemia based on miRNA expression profiles.

Obulkasim A, Katsman-Kuipers JE, Verboon L, Sanders M, Touw I, Jongen-Lavrencic M, Pieters R, Klusmann JH, Michel Zwaan C, van den Heuvel-Eibrink MM, Fornerod M.

Oncotarget. 2017 May 16;8(20):33078-33085. doi: 10.18632/oncotarget.16525.

Supplemental Content

Loading ...
Support Center